Pfizer Nears Deal to Combine Off-Patent Drug Unit With Mylan: Dow Bloomberg
Pfizer Inc. is in talks to merge its off-patent drug business with Mylan NV, Dow Jones reported, citing unidentified people familiar with the matter.
Pfizer Nears Deal to Combine Off-Patent Drug Unit With Mylan: Dow Bloomberg
Pfizer Inc. is in talks to merge its off-patent drug business with Mylan NV, Dow Jones reported, citing unidentified people familiar with the matter.